Jan 23 (Reuters) - Ascentage Pharma 6855.HK said on Thursday it aims to raise $126.4 million in an initial public offering in the U.S., becoming the first sizeable Chinese firm to seek a listing in the United States this year.
(Reporting by Gursimran Kaur in Bengaluru; Editing by Subhranshu Sahu)
((GursimranKaur.Mehar@thomsonreuters.com, https://x.com/GursimranKMehar;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。